COEP (Coeptis Therapeutics Holdings) GF Score: 12/100 (As of Jul. 04, 2026) — 37% Below Median


COEP Coeptis Therapeutics Holdings Inc COEP
12 GF Score
Price $16.40
View Full Analysis

What is Coeptis Therapeutics Holdings GF Score?

Coeptis Therapeutics Holdings COEP +1.52% 12 GF Score is 12 as of Jul. 04, 2026, which is 37% below its 10-year median of 19.00. GuruFocus rates COEP with a GF Score™ of 12/100.

Coeptis Therapeutics Holdings has the GF Score of 12, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Coeptis Therapeutics Holdings might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Coeptis Therapeutics Holdings  (NAS:COEP) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Coeptis Therapeutics Holdings GF Score Related Terms

COEP vs ANIX, COYA, PMN: GF Score Comparison

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coeptis Therapeutics Holdings GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's GF Score falls into.


COEP
12GF Score
Coeptis Therapeutics Holdings Inc COEP
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 12 mean?
Coeptis Therapeutics Holdings (COEP) has a GF Score of 12 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Coeptis Therapeutics Holdings and its competitors. This is 37% below median its historical median of 19.00. Over the past decade, Coeptis Therapeutics Holdings' GF Score has ranged from 12.00 to 41.00.
Is Coeptis Therapeutics Holdings' GF Score too high?
Coeptis Therapeutics Holdings' current GF Score of 12 is 37% below median its 10-year median of 19.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 41.00. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' GF Score compare to ANIX and COYA?
Coeptis Therapeutics Holdings' GF Score of 12 can be compared against companies in the Biotechnology industry. Historically, Coeptis Therapeutics Holdings' own GF Score has ranged from 12.00 to 41.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current GF Score is 12, which is 37% below median its own 10-year median of 19.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current GF Score of 12. The current GF Score is 12, which is 37% below median its 10-year median of 19.00. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current GF Score is 12 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score

Get the complete analysis for COEP

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40
Price